3 Neil Woodford Plays On Ageing Populations: AstraZeneca plc, Smith & Nephew plc And Capita PLC

AstraZeneca plc (LON:AZN), Smith & Nephew plc (LON:SN) and Capita PLC (LON:CPI) could super-charge your portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

WOODFORDAce fund manager Neil Woodford has hammered the market over a quarter of a century. Much of his success has come from seeing ‘the big picture’ — and pumping money into sectors that have delivered juicy returns, while avoiding those that have underperformed.

Stephen Lamacraft, a member of Woodford’s team, has recently penned an article that reveals one big-picture driver for the current positioning of the CF Woodford Equity Income fund.

Three companies the fund has backed to benefit from this driver are AstraZeneca (LSE: AZN) (NYSE: AZN.US), Smith & Nephew (LSE: SN) (NYSE: SNN.US) and Capita (LSE: CPI).

The silver age

Lamacraft writes that “with its population ageing rapidly, the world is entering a ‘silver age'”. He notes that this trend presents long-term challenges for policy-makers, but also opportunities for investors, “with older people spending considerably more money on healthcare”.

AstraZeneca

A whopping 30% of the CF Woodford Equity Income fund is invested in the healthcare sector. Woodford’s biggest single holding in the sector — in fact, the fund’s number one holding outright — is pharmaceuticals firm AstraZeneca, with a hefty weighting of 8%.

AstraZeneca’s shares are currently trading at around £44, putting the company on what looks, on the face of it, a pricey forward P/E of 17.5. However, Woodford puts a much higher valuation on the company. He was happy to see AstraZeneca reject a £55-a-share takeover bid from US giant Pfizer in May, arguing the bid undervalued the strength of Footsie firm’s drugs pipeline.

Smith & Nephew

Outside of drugs companies, Woodford’s biggest healthcare bet is Smith & Nephew, a medical devices firm, best known for hip-replacement products. Clearly, the market for the treatment of hip arthritis and hip injury — as well as the company’s other areas, which include knee and shoulder treatments — is going to grow with ageing populations.

Smith & Nephew’s shares have been trading at over £10 in recent months, and as high as £11. Again, this company’s shares look pricey on a P/E valuation: about 18. Nevertheless, Woodford has been happy to invest on this kind of rating.

Capita

Lamacraft also highlights in his article more oblique opportunities that flow from an ageing population, noting that this demographic trend will increase the already considerable strain on government budgets. He sees this as a growth driver for private-sector outsourced solutions: “This is positive for companies such as Capita which offer solutions which can deliver a better service at a much lower cost than the civil service has been able to”.

Capita is the sixth-largest holding of the CF Woodford Equity Income fund. Once again, this company looks on the pricey side on a conventional P/E of 17 at a recent share price of around £11.50. But, once again, Woodford has been happy to buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool owns shares in Smith & Nephew.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »